Login to Your Account

Clinic Roundup

Wednesday, November 14, 2012
• ImmuneWorks Inc., of Indianapolis, said it completed a Phase I trial of Type V Collagen oral solution (IW001) in patients suffering from idiopathic pulmonary fibrosis. Thirty patients were enrolled in the 24-week study, which showed the drug to be well tolerated in preliminary results, with effects on lung function.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription